ERBB2 and cancer: Patients with TN and HER2+ disease showed a higher risk of MR (about 18%) than Luminal A (7%), and their risk of recurrence declined over time, becoming as low as 0% for HER2+ and TN cancers, and 1.8% for Luminal A disease in the 10th year.